An on-the-record briefing about where the biopharmaceutical industry is in the process of researching and developing potential treatments, vaccines and diagnostics for COVID-19. Since the full genetic sequence of the novel coronavirus that can cause COVID-19 was released in January, we have made incredible advances. Today, there are more than 1,100 COVID-19 clinical trials occurring, up from just 80 in March. The unprecedented speed at which biopharmaceutical companies have responded is a testament to the robust collaboration occurring between biopharmaceutical companies directly, as well as partnerships with global health entities and governments. This unprecedented collaboration has helped fuel rapid advancement of treatments and vaccines as well as manufacturing capabilities. A question and answer session will occur following remarks from each speaker.

Speakers:

• Stephen Ubl, President and CEO, PhRMA
• David Ricks, chairman and CEO of Eli Lilly and Company
• Pascal Soriot, executive director and CEO, AstraZeneca
• Alexander Hardy, CEO, Genentech